Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
SLB, Travelers Companies And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today…
What’s Going On With Meta Platforms Stock?
Meta Platforms, Inc. (NASDAQ:META) shares are trading higher and trending on social media Friday. Here’s a look at what’s going…